H.C. Wainwright Begins Coverage of First Tracks Biotherapeutics with Buy Rating

Overview of First Tracks Biotherapeutics#

H.C. Wainwright has recently started coverage on First Tracks Biotherapeutics (NASDAQ:TRAX), assigning it a buy rating. The stock is currently priced at $18.10, with analysts predicting it could reach between $30 and $46 in the future.

Company Background and Pipeline#

First Tracks Biotherapeutics was established on April 20, having spun out from AnaptysBio. The company focuses on developing immune cell modulating monoclonal antibodies aimed at treating autoimmune and inflammatory diseases. Its lead drug, ANB033, is currently undergoing Phase 1b trials for Celiac Disease and Eosinophilic Esophagitis, conditions where the immune system mistakenly attacks the body.

Clinical Developments#

The CD122 target, which ANB033 aims to block, has been validated by similar drugs in development by competitors. For instance, Forte’s FB102, another CD122 antagonist, is in Phase 2 trials for Celiac Disease and has shown promising results in reducing harmful immune cells while being well-tolerated by patients.

First Tracks is also developing other drugs, including rosnilimab, which has completed a Phase 2b trial for rheumatoid arthritis, and ANB101, currently in Phase 1 trials with healthy volunteers. The company plans to provide updates on rosnilimab's development in the second quarter of 2026.

Financial Position and Future Outlook#

First Tracks Biotherapeutics has $180 million in cash, which should support its operations for the next two years. However, it is important to note that the company is spending this cash quickly, as indicated by a current ratio of 10.2, meaning it has more liquid assets than short-term obligations. Key data for ANB033 is expected to be released in late 2026 for Celiac Disease and mid-2027 for Eosinophilic Esophagitis.

In recent news, several major financial institutions have also shown interest in First Tracks. JPMorgan, Barclays, and UBS have all initiated coverage with positive ratings and various price targets, reflecting confidence in the potential of its lead drug, ANB033.